Private Advisor Group, LLC Bei Gene, Ltd. Transaction History

Private Advisor Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	BUY	$121.11 - $216.05 $272,618 - $486,328	2,251 Added 194.72%	3,407 $551,000
Q1 2022 May 12, 2022	SELL	$146.52 - $269.56 $35,750 - $65,772	-244 Reduced 17.43%	1,156 $218,000
Q4 2021 Feb 10, 2022	SELL	$248.56 - $389.34 $121,297 - $189,997	-488 Reduced 25.85%	1,400 $379,000
Q3 2021 Oct 14, 2021	BUY	$249.6 - $403.14 $245,606 - $396,689	984 Added 108.85%	1,888 $685,000
Q2 2021 Aug 12, 2021	BUY	$292.75 - $367.01 $31,324 - $39,270	107 Added 13.43%	904 $310,000
Q1 2021 Apr 22, 2021	BUY	$260.64 - $382.12 $207,730 - $304,549	797 New	797 $277,000
Q3 2020 Nov 02, 2020	SELL	$189.18 - $286.44 $5,864 - $8,879	-31 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$123.9 - $195.41 $3,840 - $6,057	31 New	31 $6,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.